Telotristat ethyl with PRRT in the treatment of well differentiated neuroendocrine tumors.

被引：0
|
作者：
Zhuang, Tony Z.
Muzahir, Saima
Murphy, Kristina D.
Akce, Mehmet
Alese, Olatunji B.
Gbolahan, Maria Diab Olumide B.
Shaib, Walid Labib
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] Dept Radiol & Imaging Sci, Atlanta, GA USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[5] Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[6] Dept Hematol & Med Oncol, Atlanta, GA USA
[7] Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16205
引用
收藏
页码：E16205 / E16205
页数：1
相关论文
共 50 条
  • [31] Gastric neuroendocrine tumors.: Surgical treatment and prognosis
    Bektas, H
    Länger, F
    Piso, P
    Werner, U
    Musholt, TJ
    Lehner, F
    Becker, T
    Klempnauer, J
    CHIRURG, 2002, 73 (04): : 331 - 335
  • [32] Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
    Raymond, Eric
    Dahan, Laetitia
    Raoul, Jean-Luc
    Bang, Yung-Jue
    Borbath, Ivan
    Lombard-Bohas, Catherine
    Valle, Juan
    Metrakos, Peter
    Smith, Denis
    Vinik, Aaron
    Chen, Jen-Shi
    Hoersch, Dieter
    Hammel, Pascal
    Wiedenmann, Bertram
    Van Cutsem, Eric
    Patyna, Shem
    Lu, Dongrui Ray
    Blanckmeister, Carolyn
    Chao, Richard
    Ruszniewski, Philippe
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (06) : 501 - 513
  • [33] Pancreatic neuroendocrine tumors. Current treatment concepts
    Rinke, A.
    Gress, T. M.
    INTERNIST, 2019, 60 (03): : 247 - 256
  • [34] Tumor burden in serotonin secreting pancreatic neuroendocrine tumors after initiating telotristat ethyl.
    Giacalone, Susan
    Di Gialleonardo, Valentina
    Murali, Kris
    Joish, Vijay N.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [35] Telotristat Ethyl in Combination With Everolimus in Patients With Progressive, Unresectable or Metastatic, Well- or Moderately-Differentiated Midgut Neuroendocrine Tumors (NETs): A Phase 2, Multicenter, Open-Label Study
    Kulke, Matthew
    Perez-Olle, Raul
    Stanley, Shanna
    Tesfaye, Eshetu
    Binder, Polina
    Kassler-Taub, Kenneth
    Tyle, Praveen
    Lapuerta, Pablo
    PANCREAS, 2019, 48 (03) : 442 - 443
  • [36] The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris, Philip E. E.
    Zhernosekov, Konstantin
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [37] Randomized, Parallel Arm, Phase II Study of Telotristat in Combination With Lutetium Lu 177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors (NETs)
    Chauhan, A.
    Arnold, S.
    El Khouli, R.
    Weiss, H.
    Faul, L.
    Anthony, L.
    PANCREAS, 2021, 50 (03) : 467 - 467
  • [38] Clinicopathologic features of well-differentiated lung neuroendocrine tumors
    Pakbaz, Sara
    Hodgson, Anjelica
    Asa, Sylvia
    Mete, Ozgur
    LABORATORY INVESTIGATION, 2019, 99
  • [39] Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in North American Cohort of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
    Naraev, B.
    Sharma, N.
    Engelman, E.
    Bushnell, D.
    O'Dorisio, T.
    Halfdanarson, T.
    NEUROENDOCRINOLOGY, 2012, 96 : 50 - 50
  • [40] Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors
    Mueller, D.
    Rinke, A.
    Gress, T.
    NEUROENDOCRINOLOGY, 2012, 96 : 50 - 50
12345